Eli – Page 3 – Talk Bio

Eli Lilly Intervenes in Lawsuit to Block Compounded Versions of Tirzepatide Following FDA’s Shortage Resolution

4 months ago talkbio0Tagged Eli, Eli Lilly, Glucagon-Like Peptide 1, Mounjaro, Pharmacy facility, shortage, United States Food and Drug Administration, Zepbound

Eli Lilly, tirzepatide, GLP-1 shortage, FDA, compounding pharmacies, lawsuit, Mounjaro, Zepbound

FDA Reaffirms End of Tirzepatide Shortage, Impacting Compounders

4 months ago talkbio0Tagged Compounders, Drug Shortage, Eli, Eli Lilly, Glucagon-Like Peptide 1, Mounjaro, United States Food and Drug Administration, Zepbound

FDA, tirzepatide, GLP-1, drug shortage, compounders, Eli Lilly, Mounjaro, Zepbound

Eli Lilly and Ro Partner to Expand Access to Affordable Zepbound Single-Dose Vials for Obesity Treatment

4 months ago talkbio0Tagged Affordable medication, CALR gene, Eli, Eli Lilly, Obesity, Pharmaceutical Services, Self-pay, single-dose, Telemedicine, Zepbound

Eli Lilly, Ro, Zepbound, Single-dose vials, Obesity treatment, Telehealth, Affordable medication, Self-pay pharmacy

Eli Lilly Announces $15 Billion Share Buyback Plan and 15% Dividend Increase

5 months ago talkbio0Tagged dividend, Drug Industry, Eli, Eli Lilly, Increase, Market, Share Buyback

Eli Lilly, Share Buyback, Dividend Increase, Pharmaceutical Industry, Stock Market

Advancements in BTK Inhibitors for Chronic Lymphocytic Leukemia: A Comparative Analysis of AstraZeneca, Eli Lilly, and BeiGene Therapies

5 months ago talkbio0Tagged acalabrutinib, AstraZeneca, BeiGene, Bruton's Tyrosine Kinase Inhibitors [MoA], Chronic Lymphocytic Leukemia, CLL, Continuous therapy, Effectiveness, Eli, Eli Lilly, Fixed-Duration Therapy, ibrutinib, Nemtabrutinib, Pirtobrutinib, Safety, zanubrutinib

BTK inhibitors, Chronic Lymphocytic Leukemia (CLL), AstraZeneca, Eli Lilly, BeiGene, Acalabrutinib, Ibrutinib, Zanubrutinib, Pirtobrutinib, Nemtabrutinib, Fixed-duration therapy, Continuous therapy, Efficacy, Safety

BioAge Labs Halts Phase 2 Obesity Trial Due to Liver Safety Concerns Just Two Months After IPO

5 months ago talkbio0Tagged Azelaprag, BioAge Labs, concerns, Eli, Eli Lilly, IPO, liver safety, Obesity, Phase 2 trial

BioAge Labs, Phase 2 trial, obesity, liver safety concerns, azelaprag, Eli Lilly, tirzepatide, IPO

Zepbound Outperforms Wegovy in Weight Loss Trial, Offering Superior Efficacy

5 months ago talkbio0Tagged Clinical Trials, Eli, Eli Lilly, Nordisk, Obesity, semaglutide, Wegovy, Zepbound

Zepbound, Wegovy, weight loss, tirzepatide, semaglutide, clinical trial, obesity medication, Eli Lilly, Novo Nordisk

Eli Lilly Invests $3 Billion in Wisconsin Manufacturing Expansion to Meet Growing Demand for Diabetes and Obesity Medicines

5 months ago talkbio0Tagged Diabetes, Eli, Eli Lilly, expansion, Investments, Manufacturing, Obesity, Surgical construction, Wisconsin

Eli Lilly, Wisconsin, manufacturing expansion, diabetes, obesity, pharmaceuticals, investment, job creation

Lilly’s Zepbound Outshines Novo’s Wegovy in First Head-to-Head Weight Loss Study

5 months ago talkbio0Tagged Eli, Eli Lilly, Nordisk, Obesity, SURMOUNT-5, Wegovy, Weight Loss, Zepbound

Eli Lilly, Novo Nordisk, Zepbound, Wegovy, Weight Loss, Obesity Treatment, Head-to-Head Study, SURMOUNT-5

Eli Lilly and Johnson & Johnson Sue US Government Over 340B Rebate Models

5 months ago talkbio0Tagged Drug Pricing Program, Eli, Eli Lilly, healthcare litigation, HRSA, Johnson & Johnson, pharmaceutical pricing, rebate, Study models

340B Drug Pricing Program, Eli Lilly, Johnson & Johnson, HRSA, rebate models, pharmaceutical pricing, healthcare litigation